trial

To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)

NCTId NCT00150176
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 831 (actual)
Sponsored by Organon and Co
Primary completion 2008-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
831 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2005-04
Primary completion
2008-06
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Asenapine

Sponsors

Organon and CoLead Sponsor

Sites

0 total

Linked catalysts

1
To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient — primary completion2008-06

Facts & assertions

4 sourced
Enrollment
831
Phase
PHASE3
Primary Completion Date
2008-06
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
lead_sponsor
Organon and Co
company
indication
Schizophrenia
indication
Schizophrenia
indication